Myelofibrosis Highlights From SOHO 2023

John Mascarenhas, MD


September 29, 2023

Developments in emerging therapies and predictive models in myelofibrosis (MF) are among the highlights of the 2023 annual meeting of the Society of Hematologic Oncology (SOHO) discussed by Dr John Mascarenhas of the Icahn School of Medicine in New York.

Dr Mascarenhas draws from several in-depth conference presentations to outline key therapeutic advances. He begins with new predictive models in MF that are expected to better predict therapeutic outcomes and identify optimal candidates for stem cell transplant.

He then turns to the management of anemia, which affects most patients with MF over the course of their disease. Dr Mascarenhas highlights results for newer agents providing improved control of anemia, including luspatercept, pacritinib and momelotinib.

Dr Mascarenhas then turns to management of accelerated phase and blast phase in myeloproliferative neoplasms, for which the combination of ruxolitinib and decitabine shows early signs of benefit.

The next presentation he discusses focused on use of Janus kinase inhibitors in MF, including recently approved agents pacritinib and momelotinib.

Finally, Dr Mascarenhas explores novel therapies for MF, including pelabresib, and what he calls a paradigm shift in MF to the use of combination therapy in the upfront setting for the purpose of deepening spleen responses, extending duration of benefit and, ultimately, survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.